Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Price:
1.04 USD
-0.95%
Market Closed
Updated:
May 29, 2024
Adaptimmune Therapeutics PLC
Other Liabilities
|
Adaptimmune Therapeutics PLC
Other Liabilities Peer Comparison
Comparables:
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Other Liabilities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
Other Liabilities
$167.2m
|
CAGR 3-Years
33%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Other Liabilities
$8.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Other Liabilities
$219.2m
|
CAGR 3-Years
63%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Other Liabilities
$110.8m
|
CAGR 3-Years
52%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Other Liabilities
£41.1m
|
CAGR 3-Years
18%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Other Liabilities
£24.3m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-9%
|
See Also
What is Adaptimmune Therapeutics PLC's Other Liabilities?
Other Liabilities
167.2m
USD
167.2m
USD
Based on the financial report for Mar 31, 2024, Adaptimmune Therapeutics PLC's Other Liabilities amounts to 167.2m USD.
What is Adaptimmune Therapeutics PLC's Other Liabilities growth rate?
Other Liabilities CAGR 5Y
44%
44%
Over the last year, the Other Liabilities growth was 19%. The average annual Other Liabilities growth rates for Adaptimmune Therapeutics PLC have been 33% over the past three years , 44% over the past five years .
You don't have any saved screeners yet
